[ad_1]
Samsung Bioepis Co., Ltd. at present launched its First Quarter 2026 Biosimilar Market Report, marking the twelfth version of the Quarterly Biosimilar Market Report in america (US). The report gives an summary of the market standing of all biosimilars obtainable within the US, together with approval and launch standing, pricing (each Common Gross sales Value [ASP] and Wholesale Acquisition Price [WAC]), and market uptake per molecule. The Deep Dive part on this version gives an summary of the evolving US Pharmacy Profit Supervisor (PBM) rebate contract mannequin and the way its frameworks could doubtlessly impression the biosimilar market.
“Because the US healthcare market enters 2026, stakeholders’ approaches to prescription drug pricing and administration proceed to evolve. Alongside established PBM contracting constructions, new fashions emphasizing different pricing reimbursement, transparency, and a shift in the direction of extra fiduciary accountability have emerged in response to altering market situations,” stated Thomas Newcomer, Vice President, Head of US Industrial Operations, at Samsung Bioepis. “On this quarter’s report, we offer an summary of those developments and contemplate how evolving PBM rebate frameworks could affect utilization patterns, together with potential implications for biosimilars.”
Key highlights from market evaluation:
As of December 2025, the variety of permitted biosimilars within the US has reached as much as 90 biosimilars throughout 20 distinctive organic molecules, of which 63 biosimilars (70%) had been launched available in the market
Biosimilar launches have led to important worth decreases over time throughout a number of molecules. On common, ASPs decreased by 52% inside 5 years of the primary biosimilar launch, with extra mature markets reaching even higher worth reductions over time (as much as 77%). Nevertheless, declines in ASP inside sure markets don’t at all times comply with a constant pattern as they could be affected by intentional ASP repositioning and the deliberate elimination of merchandise from the market
With 4 aflibercept biosimilar merchandise awaiting clearance to launch, reference aflibercept faces just one biosimilar competitor providing a WAC low cost of 12%
Within the immunology area, whereas personal label manufacturers stay frequent for adalimumab and ustekinumab, most ustekinumab biosimilars haven’t adopted a twin or excessive WAC technique as in comparison with the adalimumab market
[ad_2]
